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Peoplewith Down syndrome(DS) developAlzheimer’s disease(AD) with an early ageofonset.Atetranucleotide repeat, attt5−8,in
intron7oftheamyloidprecursor proteinhasbeen associatedwiththeageofonsetofAD inDS inapreliminary study. Theauthors
examinethe impact ofthis polymorphism in a larger cohort ofindividuals with DS.Adults with DS were genotyped forattt5−8 and
APOE. The results were analysed with respect to the age of onset of dementia. The presence of three copies of the six-repeat allele
resulted in onset of dementia seven years earlier than in the presence of other genotypes. Further study is essential to elucidate the
mechanism by which this polymorphism functions, with an exciting opportunity to identify novel treatment targets relevant for
people with DS and AD.
1.Introduction
Down syndrome (DS), deﬁned cytogenetically by trisomy
21, is the most common chromosomal disorder associated
with learning disability, occurring in approximately 1/1000
live births [1]. The prevalence of Alzheimer’s disease (AD)
in people with DS increases signiﬁcantly with age. However,
the nature of the early clinical presentation, course, and
incidence rates of dementia are uncertain. Despite the nearly
universal occurrence of AD pathology by age 40 [2, 3],
there is wide variation in age of onset of clinical dementia.
Most studies have indicated that the average age at onset of
dementia is between 50 and 55 years of age, with a range
from 38–70 years [4]. Many studies have now conﬁrmed
that age-related cognitive decline and dementia aﬀecting
peoplewith DS occurs30–40years earlier thanin the general
population. Age-speciﬁc rates of dementia begin to increase
in the patient’s 30s from 1-2% to 40% in the 50s [5], hence
dementia is becoming an increasingly important issue in
people with DS as life expectancy continues to increase.
The neuropathological manifestations of AD in DS have
been atleastin part attributedtotriplicationand overexpres-
sion of the gene for amyloid precursor protein (APP)locat ed
on chromosome 21 [6]. In fact, an additional copy of APP
can cause early onset AD with cerebral amyloid angiopathy,
even when only small regions of chromosome 21 including
only the APP gene are triplicated [7–10]. Triplication of
chromosome 21 leads to an increase in expression levels of
its genes. APP is expressed at levels which are four- to ﬁve-
fold higher in DS than in the general population [11]. This
is not only due to triplication of the gene, but is also caused
by regulators of APP expression, for example ETS2,p r e s e n t
on chromosome 21, which have increased expression levels
[12]. Processing of APP can result in the production of beta-
amyloid (Aβ) which is deposited extracellularly as a core
disease feature in the brains of people with AD.
Along with overexpression, other APP changes are seen
in AD, which include variations in the proportion of APP
splice variants. Three of these isoforms are APP695, APP751,
and APP770. APP695 ispredominantly expressed inneurons2 International Journal of Alzheimer’s Disease
whilst APP751 and APP770 are ubiquitously expressed. A
kunitz protease inhibitor doma i n( K P I )e n c o d e db ye x o n7i s
presentinbothAPP751andAPP770,butnotinAPP695.The
ratio of APP751:APP695 mRNA is found to be increased in
the brains of people with AD [13, 14], and there appears to
bearelationshipbetweenthisratioandthedensityofplaques
in the hippocampus and entorhinal cortex [15]. In fact, mice
expressing human APP751,butnot APP695, developanAD-
like pathology, which most closely resembles that found in
the brains of young people with DS [16]. This pathology not
only involves Aβ, but also abnormal tau isoforms. Therefore,
itwouldseem thatnot onlyoverexpression of APPin DS,but
alsovariation inisoforms,mayhavearolein determiningthe
onset of AD.
Intron 7 of APP has been sequenced previously to
determine if polymorphic sites which may have the potential
to regulate exon 7 splicing were present [17]. The tetranu-
cleotide repeat (attt5–8) was identiﬁed and the attt6 allele
was found to be the most common, present in 96% of the
genotyped population. When this region was genotyped in a
preliminary study of 105 people with DS, there was found
to be an association between the number of attt6 alleles
and the age of onset of dementia [18]. Speciﬁcally, those
individuals carrying three copies of the attt6 allele developed
dementia with an earlier age of onset than those with any
other combination of the repeats.
In DS polymorphisms on chromosome 21 may have an
ampliﬁed eﬀect.Asmost peoplewithDSdevelopADwithan
early age of onset, these ampliﬁed genetic eﬀects may allow
us to more clearly detect the associated phenotypes, such
as accelerated onset of dementia or severity. Such genetic
eﬀects may be too subtle to detect in the general population,
but the mechanistic information provided will be valuable
in drug design for all those at risk of developing AD.
Following the preliminary study [18]w ee x a m i n ew h e t h e r




2.1. Samples and Clinical Assessments. Clinical evaluation
was completed and DNA samples were obtained from 291
adults with DS (Newcastle-181, Birmingham-78, MEAD-
OWS Clinical Trial-32), substantially extending a previous
pilotstudy [18].In thepreviousstudy the diﬀerencein ageof
onset between the genotypes was 13.4 years, with a standard
deviation of 7.2 years [18]. Using these values, a power
calculationshows that a study using a total of 18 participants
(9 attt6 homozygotes and 9 heterozygotes) has a 95 percent
chance to detect a diﬀerence at a two-sided 0.05 signiﬁcance
level.
Thisstudywasapprovedbytheappropriatelocalresearch
ethics committee and consent was obtained from the
participants. Detailed prospective clinical assessments were
completed which included the DAMES battery (Newcastle,
MEADOWS) and the Adaptive Behaviour Scale (ABS) [19]
(Birmingham, MEADOWS),which enabled the operational-
izeddiagnosisofdementiabyanexpertintheﬁeld(MH,VP)
according to the International Classiﬁcation of Disease [20].
Clinicians were blind to genotyping results.
2.2. Genotyping. Blood samples were collected into K2-
EDTA vacutainers(BDDiagnostics), and DNAwasextracted
using the FlexiGene DNA kit (Qiagen). Genotyping of the
APP intron 7 tetranucleotide repeat was performed using a
CEQ8000 Genetic Analyser (Beckman Coulter). Brieﬂy, the
region surrounding the repeat was ampliﬁed by PCR (Dye
4-labelled forward primer 5 CCATGTCGTTAACAGACT-
TCC3 , reverse primer 5 GAGTAGTTCATACTTCCTAC3 ,
both from Proligo). PCR enzymes and buﬀers were from
Qiagen. Cycling was carried out as follows: 94◦Cf o r2
minutes, 35 cycles of (94◦C for 30 seconds, 55◦Cf o r3 0
seconds, 72◦Cf o r1m i n u t e ) ,7 2 ◦Cf o r1 0m i n u t e s .T h i s
reaction produced a 105bp product for the attt6 allele.
Labelled PCR products were combined with a 400bp size
standard and sample loading solution (Beckman Coulter)
and processed on the CEQ8000 genetic analyser.
APOE genotyping was carried out using PCR (for-
ward primer 5 TCCAAGGAGCTGCAGGCGGCGCA-3 
and reverse primer 5 -ACAGAATTCGCCCCGGCCTGG-
TACACTGCCA-3 ,Sigma-Aldrich).AmpliTaq Goldenzyme
and buﬀer (Applied Biosystems) and 10% DMSO (Sigma-
Aldrich) were used, and cycling proceeded as follows: 94◦C
for 5 minutes, 45 cycles of 94◦C for 30 seconds, 65◦Cf o r1
minute, 72◦Cf o r1m i n u t e ,a n d7 2 ◦Cf o r1 0m i n u t e s .T h e
resulting product was digested with HaeII or AﬂIII (New
England Biolabs). Fragments were separated on 1% standard
agarose (Invitrogen Life Technologies) gels containing 3%
Metaphor agarose (Cambrex).
2.3. Statistics. Statistical analysis of clinical and genotyping
data was carried out using SPSS version 17. For the primary
analysis we compared the age of onset of dementia in people
with and without the attt6 polymorphism using independent
sample t-tests. The same evaluation was used to examine the
impact of APOE –ε4.
3.Results
Two-hundred and ninety-one DNA samples were genotyped
for the intron 7 repeat polymorphism attt5–8 in APP and
APOE, using fragment analysis with a CEQ8000 genetic
analyser and restriction fragment length polymorphism,
respectively. Clinical data for each participant was collected
by the examining psychiatrists. The mean age of the partici-
pantswas52.20years±13.93(rangefrom24to89years),and
38%werefemale.Basedupontheoperationalizedpsychiatric
evaluations, 103 participants had dementia (35%), with a
mean age of onset of 50.46 years ±7.85 (range 34–74 years).
A further 76 individuals were 45 or older, but did not meet
operationalized criteria for a diagnosis of dementia. Thirty
people (10.3%) were heterozygous for the attt5–8 genotype,
which is in agreement with frequencies found in previous
genotyping studies [17, 18]. Of the 103 participants with
dementia, 9 were heterozygous for the tetranucleotide repeat
polymorphism, which is an appropriately sized sample whenInternational Journal of Alzheimer’s Disease 3
consideringthepowercalculationshown inSection2.Duet o
v a r i a t i o ni nt h ep e a ks i z e sf o rt h ef r a g m e n ta n a l y s i si ti sn o t
p o s s i b l et ot e l li ft h eh e t e r o z y g o t e sh a v eo n eo rt w oc o p i e so f
the rarer alleles, so we have chosen to group all heterozygotes
together based upon the presence of alleles attt5, attt7,
or attt8. This may be due to variations in ampliﬁcation
eﬃciencies between the diﬀerent repeat alleles.
As i g n i ﬁ c a n td i ﬀerence was evident in the age of onset of
dementia between individuals with 3 attt6 alleles and those
with any other allele combination (n = 103, independent
samples t-test, t =− 2.65, df = 102, P = .009) (a Kaplan-
Meier plot is shown in Figure 1). The mean age of onset in
individuals with 3 attt6 alleles was 49.85 years ±7.81 whilst
in people with a diﬀerent repeat combination the mean age
was 56.89 years ±5.09. None of the individuals with less than
3 attt6 repeats developed dementia before 52 years.
We also examined the link between the attt5–8 polymor-
phism and the risk of developing dementia before the age
of 45. Only individuals who had dementia or had reached
the age of 45 without developing dementia were included
in this analysis, as individuals under the age of 45 and
without dementia have not yet reached the high-risk period
for dementia development. A trend was found between the
risk of developingdementia before the age of 45 and the APP
polymorphism (n = 179, χ2 = 2.95, df = 1, P = .086).
Gender was not related to the age of onset of dementia
(t =− 1.19, df = 84, P = .24). The presence of an APOE-ε4
allele was not associated with the age of onset of dementia
(t = 0.49, df = 80, P = .62). Neithergender nor the presence
of an APOE-ε4 allele were associated with attt5–8 genotype
(χ2 = 1.22, df = 1, P = .27 and χ2 = 0.27, df = 1, P = .60,
resp.).
4.Discussion
These data highlight a striking association between 3 copies
oftheattt6 allele inintron 7ofAPP and asubstantially earlier
ageofonset ofdementia.Peoplewith 3attt6 allelesdeveloped
dementia 7 years earlier. The next step is to determine how
the acceleration of dementia in DS is brought about in those
people with3 attt6 alleles and to understand the implications
for AD in the wider population, so that the related novel
therapeutic opportunities can be fully utilized.
The tetranucleotide repeat region is located 1200bp into
the 2598bp sequence of intron 7 and is 193bp 3  from an
Alu sequence which is key for binding of splicing factors
and splicing of exons 7 and 8 from APP [7, 21]( F i g u r e2).
The tetranucleotide repeat lies in a 524bp region between
single nucleotide polymorphisms (SNPs) rs9982544 and
rs2409162, but neither of these is polymorphic in the CEU
population and so cannot be used for haplotype analysis
of this region for our samples. The closest SNPs which are
suﬃciently polymorphic in the CEU population, rs3787637
andrs8132200,enclosearegionof2313bpextendingbeyond
intron 7, and further analysis of how the tetranucleotide
repeat is associated with these will be required before we can
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Figure 1: Kaplan-Meier survival plot showing the eﬀect of the
tetranucleotide attt5–8 upon age of onset of dementia in 103 people
with DS. Thosepeople carrying three copies of theattt6 allele ofthis
polymorphism develop dementia with an earlier age of onset than
those with any other combinationof alleles (P = .009).
It is unclear why the 6-repeat allele is associated with risk
when neither the 5- or 7-repeat alleles are, and why risk is
not associated with increasing or decreasing repeat length
although similar results have been found for other genes and
disease risk: CYP19 and breast cancer risk, and MIF and
gastric cancer risk [22, 23].
A further possibility is that the tetranucleotide repeat
attt6 is a marker for a functional polymorphism which is
altering the expression, activity, or regulation of APP, which
in turn alters the development of pathology and onset of
dementia. Further examination of other SNPs in APP and
how they are linked to attt6 is required to understand fully
the mechanism involved.
Levelsofexon 7-containing isoforms ofAPP are found to
be increased in AD brain [10] and associated with increased
depositsofAβ[24].Thepr ot eas einhibit oracti vityoftheKPI
domain has been shown to act on an extracellular trypsin-
like serine protease which degrades secreted APP [25]a n d
therefore, isoform variation may play an important role in
regulating the activity of this protease. KPI-containing APP
may also bind to low-density lipoprotein receptor-related
protein (LRP), which is involved in the clearance of Aβ from
the brain into peripheral tissues, and this has been shown
to reduce Aβ clearance [26]. Receptors and other proteins
involvedinthisclearanceprocessmayprovetobeusefuldrug
targets, and early intervention in this pathway may provide
a method of preventing increased deposition of Aβ in the
brain.
The role of this polymorphism, or other associated poly-
morphisms, in regulation of APP splicing is not known, and
examining this will play an important role in determining
how dementia risk is aﬀected. It will also be important to4 International Journal of Alzheimer’s Disease
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Figure 2:Diagrammaticrepresentation ofintrons7to8ofAPP showingthelocationsofthetetranucleotide repeat, Alusequence andclosest
SNPs. Grey bars indicate introns and black bar indicates exon 8. Figure is not to scale.
determine the impact of the tetranucleotide repeat upon Aβ
deposition in the brain in postmortem studies. This will give
an indication of how large a role this polymorphism plays in
Aβ regulation.
The APOE-ε4 allele had no eﬀect upon the age of
onset of dementia in this study. Previously it has been
suggested that APOE does not aﬀect the age of onset of
dementia in cases of familial Alzheimer’s disease (FAD) due
to chromosome 14 mutations [27]. It may be that when APP
regulation is strongly aﬀected through triplication in DS or
through particular mutations, APOE eﬀects are masked by
t h ep r e s e n c eo ft h em o r ep o w e r f u lA P Pe ﬀects. Triplication
of APP in DS may have resulted in ampliﬁed eﬀects of this
polymorphism, but it may still have important potential
implications for AD which have not yet been detected in the
general population.
When this polymorphism was previously studied by
Li et al. [17] the less common repeat sizes were only found in
asmall numberofsamples,which mayresultinlowstatistical
power. Given that this polymorphism appears to take eﬀect
in a population with an increased risk of AD and increased
expression of APP leading to increased Aβ levels, it would
be valuable to examine the eﬀects of this polymorphism in a
second population with an increased incidence of AD and
Aβ concentrations, namely those in the wider population
over the age of 80. The incidence of AD in this age group
is approximately 25%, which is similar to that for people
with DS in their 40s, and those over the age of 80 also have
increasedbrainAβ1–40and1–42levels[28].Alargestudyin
sucha populationwouldallow ustoanalyse theeﬀectsofthis
attt5–8 in the general population at risk of developing AD.
In this study we have taken a unique opportunity to
examine AD-type dementia in a population in which a high
proportionofpeoplewill developdementia with anearly age
of onset. This has allowed us to examine more closely the
association of this polymorphism to the development and
progression of dementia. The ampliﬁcation of the eﬀects of
APP polymorphisms in DS allows us to detect diﬀerences
which may be more subtle in the wider population.
Studiessuch as these not only provide the opportunity to
discover therapies which may beneﬁt those with DS, but also
those in the older general population in which the incidence
of AD is increasing. The beneﬁts of studying the relatively
small DS population must not be forgotten in the search for
new therapies to tackle AD.
5.Conclusions
The attt5–8 polymorphism in APP is associated with the
age of onset of AD in DS, from which we conclude that
it may function by accelerating the pathological process or
is a marker for an, as yet unidentiﬁed, functional variant.
The mechanism by which this is achieved has yet to be
established, but the proteins involved may prove to be useful
targets for future drug development.
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